SMS Lifesciences India Ltd
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
- Market Cap ₹ 204 Cr.
- Current Price ₹ 676
- High / Low ₹ 707 / 464
- Stock P/E 73.8
- Book Value ₹ 553
- Dividend Yield 0.22 %
- ROCE 7.92 %
- ROE 6.12 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.25% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 3.03% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|
378 | 261 | 266 | 350 | 316 | 280 | |
343 | 235 | 235 | 316 | 287 | 258 | |
Operating Profit | 35 | 25 | 30 | 35 | 29 | 22 |
OPM % | 9% | 10% | 11% | 10% | 9% | 8% |
2 | 2 | 2 | 14 | 5 | 6 | |
Interest | 6 | 5 | 5 | 6 | 7 | 9 |
Depreciation | 6 | 8 | 8 | 10 | 11 | 14 |
Profit before tax | 25 | 15 | 20 | 33 | 17 | 5 |
Tax % | 30% | 31% | 31% | 23% | 31% | |
18 | 10 | 14 | 25 | 11 | 2 | |
EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 16.18 |
Dividend Payout % | 3% | 0% | 3% | 2% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 7% |
TTM: | -20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -1% |
TTM: | -79% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 11% |
1 Year: | 32% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 103 | 113 | 126 | 149 | 166 | 164 |
47 | 65 | 65 | 80 | 100 | 106 | |
116 | 72 | 108 | 125 | 126 | 109 | |
Total Liabilities | 270 | 253 | 302 | 357 | 395 | 383 |
118 | 124 | 130 | 142 | 228 | 221 | |
CWIP | 3 | 16 | 38 | 51 | 1 | 9 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
148 | 113 | 134 | 164 | 166 | 153 | |
Total Assets | 270 | 253 | 302 | 357 | 395 | 383 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
30 | 15 | 35 | -11 | 15 | |
-44 | -27 | -26 | -7 | -31 | |
15 | 12 | -3 | 11 | 17 | |
Net Cash Flow | 1 | -0 | 6 | -8 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 40 | 30 | 47 | 35 | 53 |
Inventory Days | 116 | 149 | 164 | 159 | 184 |
Days Payable | 140 | 101 | 163 | 146 | 127 |
Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 |
Working Capital Days | 27 | 47 | 37 | 56 | 76 |
ROCE % | 12% | 13% | 12% | 8% |
Documents
Announcements
- Closure of Trading Window 11h
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 1d
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 2d
- Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 2d
- KYC Update (Communication To Shareholders) 27 Feb
Business Overview:[1][2][3]
Company is the demerged entity of SMS Pharmaceuticals Ltd, catering to semi-regulated markets across India, Europe, and Asia with a portfolio of 12 APIs in the GAS and Anti-erectile dysfunction (EDF) therapeutic segment. It does manufacturing of Antiulcerative products, for Indian and global markets and supplies KSMs and Intermediates